Novavax COVID-19 Vaccine Participants in US trials are considered fully vaccinated two weeks after the -CDC dose

by

The vials with a sticker that reads “COVID-19 / Coronavirus Vaccine / Injection Only” and a medical syringe are seen in front of the Novavax logo that appears in this illustration from October 31, 2020. REUTERS / Dado Ruvic / Illustration

August 30 (Reuters) – Participants in Novavax Inc.’s final COVID-19 vaccine trial (NVAX.O) may be considered fully vaccinated two weeks after completing their two-dose vaccination regimen, according to say Monday the U.S. Centers for Disease Control and Prevention.

The CDC said the guide does not imply approval of the shot, which has not yet been authorized for use in the United States. Novavax expects to present the U.S. Emergency Use Authorization in the fourth quarter of 2021. more information

The guide provides clarity to participants in vaccine clinical trials in the United States at a time when more U.S. employers are forcing staff to be vaccinated against COVID-19.

Report by Carl O’Donnell Edited by Chris Reese

Our standards: the principles of trust of Thomson Reuters.

.Source